Aliases & Classifications for Ocular Hypotension

MalaCards integrated aliases for Ocular Hypotension:

Name: Ocular Hypotension 12 41 14 69
Hypotony of Eye 12

Classifications:



External Ids:

Disease Ontology 12 DOID:790
ICD10 32 H44.4 H44.40
ICD9CM 34 360.3 360.30
MeSH 41 D015814
UMLS 69 C0028841

Summaries for Ocular Hypotension

MalaCards based summary : Ocular Hypotension, also known as hypotony of eye, is related to primary eye hypotony and ocular hypertension, and has symptoms including eye manifestations An important gene associated with Ocular Hypotension is HTR2B (5-Hydroxytryptamine Receptor 2B), and among its related pathways/superpathways are Signaling by GPCR and DAG and IP3 signaling. The drugs Dexamethasone and Timolol have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and brain.

Related Diseases for Ocular Hypotension

Diseases related to Ocular Hypotension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 primary eye hypotony 11.1
2 ocular hypertension 10.0
3 open-angle glaucoma 10.0
4 resting heart rate, variation in 10.0 ADRB1 ADRB2
5 hydrops, lactic acidosis, and sideroblastic anemia 9.9
6 macular retinal edema 9.9
7 meningococcal infection 9.9 ADRB1 ADRB2
8 aortic coarctation 9.9 ADRB1 ADRB2
9 glaucoma, primary open angle 9.8
10 cataract 9.8
11 diabetic macular edema 9.8
12 orthostatic intolerance 9.8 ADRB1 ADRB2
13 leprosy 3 9.6
14 uveitis 9.6
15 anterior uveitis 9.6
16 congestive heart failure 9.6 ADRB1 ADRB2
17 acrodysostosis 9.5 PDE4B PDE4D

Comorbidity relations with Ocular Hypotension via Phenotypic Disease Network (PDN):


Glaucoma, Primary Open Angle Open-Angle Glaucoma

Graphical network of the top 20 diseases related to Ocular Hypotension:



Diseases related to Ocular Hypotension

Symptoms & Phenotypes for Ocular Hypotension

UMLS symptoms related to Ocular Hypotension:


eye manifestations

Drugs & Therapeutics for Ocular Hypotension

Drugs for Ocular Hypotension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3 50-02-2 5743
2
Timolol Approved Phase 4 26839-75-8 5478 33624
3
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
4
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
5
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
6
Carteolol Approved Phase 4 51781-06-7 2583
7 Dexamethasone acetate Phase 4,Phase 3 1177-87-3
8 glucocorticoids Phase 4,Phase 3
9
protease inhibitors Phase 4,Phase 3
10 Gastrointestinal Agents Phase 4,Phase 3
11 HIV Protease Inhibitors Phase 4,Phase 3
12 Hormone Antagonists Phase 4,Phase 3
13 Hormones Phase 4,Phase 3
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
15 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Antiemetics Phase 4,Phase 3
17 Anti-Inflammatory Agents Phase 4,Phase 3
18 Antineoplastic Agents, Hormonal Phase 4,Phase 3
19 BB 1101 Phase 4,Phase 3
20 Autonomic Agents Phase 4,Phase 3
21 diuretics Phase 4
22 Adrenergic Agents Phase 4
23 Adrenergic Antagonists Phase 4
24 Adrenergic beta-Antagonists Phase 4
25 Sympatholytics Phase 4
26 Natriuretic Agents Phase 4
27 Tetrahydrozoline Phase 4,Phase 1,Phase 2
28 Neurotransmitter Agents Phase 4,Phase 1,Phase 2
29 Ophthalmic Solutions Phase 4,Phase 1,Phase 2
30 Anti-Arrhythmia Agents Phase 4,Phase 1,Phase 2
31 Anticonvulsants Phase 4
32 Pharmaceutical Solutions Phase 4,Phase 1,Phase 2
33 Antihypertensive Agents Phase 4
34 Carbonic Anhydrase Inhibitors Phase 4
35
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
36
Colchicine Approved Phase 3 64-86-8 2833 6167
37
Fluorouracil Approved Phase 3 51-21-8 3385
38
Dalteparin Approved Phase 3 9005-49-6
39 calcium heparin Phase 3
40 Fibrinolytic Agents Phase 3
41 Heparin, Low-Molecular-Weight Phase 3
42 Anticoagulants Phase 3
43 Antimitotic Agents Phase 3
44 Antirheumatic Agents Phase 3
45 Calcium, Dietary Phase 3
46
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
47 Analgesics Phase 1, Phase 2
48 Vasodilator Agents Phase 1, Phase 2
49
Hyaluronic acid Approved, Vet_approved 9004-61-9 53477741 24759
50
Bimatoprost Approved, Investigational 155206-00-1 5311027

Interventional clinical trials:

(show all 16)

# Name Status NCT ID Phase Drugs
1 A Study to Evaluate Efficacy and Safety Effects Using Mikelan® LA Ophthalmic Solution (OS) 2% Versus Timoptol® XE Ophthalmic Solution (OS) 0.5% in Ocular Hypertension Patients Completed NCT00972426 Phase 4 carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)
2 COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy Completed NCT01228149 Phase 4 Trabeculectomy with preoperative Diamox/DexaEDO treatment;Trabeculectomy with preoperative Cosopt S treatment
3 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
4 Aqueous Mushroom Extract and Intraocular Pressure Unknown status NCT01017068 Phase 1, Phase 2 OME;OME;OME;OME;OME;OME
5 A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Completed NCT01123785 Phase 1, Phase 2 INO-8875;Placebo
6 Long-Term IOP Fluctuation and VF Progression After Triple Procedure Completed NCT00428740
7 PIO Laser Sclerectomy IOP SLT Sclerectomy Completed NCT01798732
8 Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab Completed NCT00892398 ranibizumab
9 Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes Completed NCT00773136 Bimatoprost Suspension
10 Comparison of Phacotrabeculectomy and Trabeculectomy in the Treatment of Primary Angle-closure Glaucoma (PACG) Completed NCT01298635
11 Selective Laser Trabeculoplasty After Failed Phacoemulsification With Eximer Laser Trabeculectomy Completed NCT02434250
12 Primary Angle Closure Glaucoma and Aqueous Dynamics Completed NCT00719290
13 Clinical Evaluation of CATS Tonometer Prism Recruiting NCT02990169
14 Melatonin Decreases Eye Pressure in Normotensive Patients Recruiting NCT03193112 Agomelatine 25 MG Oral Tablet
15 Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery Not yet recruiting NCT02846090 Dexmedetomidine to reduce the IOP
16 Effect of Hyaluronidase on Intraocular Pressure Not yet recruiting NCT03266406 Hyaluronidase

Search NIH Clinical Center for Ocular Hypotension

Cochrane evidence based reviews: ocular hypotension

Genetic Tests for Ocular Hypotension

Anatomical Context for Ocular Hypotension

MalaCards organs/tissues related to Ocular Hypotension:

38
Eye, Endothelial, Brain

Publications for Ocular Hypotension

Articles related to Ocular Hypotension:

(show top 50) (show all 67)
# Title Authors Year
1
Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost. ( 28538979 )
2017
2
Repeated Intravitreous Ranibizumab Injections for Diabetic Macular Edema and the Risk of Sustained Elevation of Intraocular Pressure or the Need for Ocular Hypotensive Treatment. ( 25719991 )
2015
3
ADRB1 and ADBR2 gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects. ( 24749907 )
2014
4
The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study. ( 25319729 )
2014
5
Impact of ocular hypotensive lipids on clinically significant diabetic macular edema. ( 22267460 )
2012
6
Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. ( 21794845 )
2011
7
Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. ( 20426763 )
2010
8
Morphine-induced ocular hypotension is modulated by nitric oxide and carbon monoxide: role of mu3 receptors. ( 20148660 )
2010
9
Ocular hypotension and hypotony in multibacillary leprosy patients; at diagnosis, during and after completion of multidrug therapy. ( 21434594 )
2010
10
Prolonged ocular hypotension: would ciliary tissue transplantation help. ( 19098698 )
2009
11
Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. ( 19234340 )
2009
12
Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. ( 18992242 )
2009
13
Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study. ( 19210139 )
2009
14
Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? ( 18460537 )
2008
15
Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension. ( 17565920 )
2007
16
Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. ( 17056362 )
2006
17
Serotonin-2 (5-HT2) receptor-mediated signal transduction in human ciliary muscle cells: role in ocular hypotension. ( 17238805 )
2006
18
Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension. ( 16968567 )
2006
19
Fadolmidine-induced ocular hypotension in normotensive rabbits. ( 15720782 )
2005
20
PD128,907 induces ocular hypotension in rabbits: involvement of D2/D3 dopamine receptors and brain natriuretic peptide. ( 15006155 )
2004
21
Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. ( 15037111 )
2004
22
Ocular hypotensive effect and safety of brinzolamide ophthalmic solution in open angle glaucoma patients. ( 15216404 )
2004
23
Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. ( 12676887 )
2003
24
Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. ( 14733708 )
2003
25
New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. ( 14646172 )
2003
26
Ocular hypotension induced by electroacupuncture. ( 12222760 )
2002
27
Cystoid macular edema in the era of ocular hypotensive lipids. ( 11915838 )
2002
28
Cystoid macular edema associated with ocular hypotensive lipids. ( 11860980 )
2002
29
Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. ( 10614682 )
2000
30
2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit. ( 10882008 )
2000
31
8OH-DPAT-Induced ocular hypotension: sites and mechanisms of action. ( 10433858 )
1999
32
Mechanism of exercise-induced ocular hypotension. ( 10102302 )
1999
33
Ocular hypotension induced by intravitreally injected C-type natriuretic peptide. ( 9533834 )
1998
34
Lisuride acts at multiple sites to induce ocular hypotension and mydriasis. ( 9742290 )
1998
35
Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. ( 9851310 )
1998
36
Potential mechanisms of moxonidine-induced ocular hypotension: role of norepinephrine. ( 9436152 )
1997
37
Ocular hypotensive effect of topical ketanserin in timolol users. ( 9085107 )
1997
38
Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. ( 8921215 )
1996
39
Centrally mediated ocular hypotension: potential role of imidazoline receptors. ( 7677360 )
1995
40
Evaluation of IBMX-enhanced ocular hypotension after adrenergic agonists in the rabbit eye. ( 7542619 )
1995
41
Molecular characterization and ocular hypotensive properties of the prostanoid EP2 receptor. ( 8590276 )
1995
42
Correlates of acute exercise-induced ocular hypotension. ( 7928182 )
1994
43
Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. ( 7925603 )
1994
44
Ocular hypotension during short- and long-term hypocapnia. ( 19920601 )
1994
45
Long-term visual outcome of ocular hypotension after thermosclerostomy. ( 8488912 )
1993
46
PhXA34-induced ocular hypotension. ( 1463535 )
1992
47
Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. ( 1349879 )
1992
48
Reattachment of the detached ciliary body with suturing for treatment of contusional ocular hypotension. ( 1896179 )
1991
49
Soluble forms of isobutylmethylxanthine enhance the ocular hypotension induced by catecholamines. ( 1722476 )
1991
50
Isobutylmethylxanthine enhances adrenergic-induced ocular hypotension in rabbits and beagles. ( 1712310 )
1991

Variations for Ocular Hypotension

Expression for Ocular Hypotension

Search GEO for disease gene expression data for Ocular Hypotension.

Pathways for Ocular Hypotension

Pathways related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
2
Show member pathways
12.47 ADRB1 ADRB2 PDE4B PDE4C PDE4D
3
Show member pathways
12.27 PDE4B PDE4C PDE4D
4 12.22 ADRB1 ADRB2 PDE4B
5
Show member pathways
12.19 PDE4B PDE4C PDE4D
6
Show member pathways
12.12 ADRB2 PDE4B PDE4C PDE4D
7
Show member pathways
12.05 ADRB1 ADRB2 PDE4B PDE4D
8
Show member pathways
11.9 ADRB1 ADRB2 HTR2B
9 11.71 ADRB1 ADRB2 PDE4B
10
Show member pathways
11.66 ADRB1 ADRB2 PDE4B PDE4C PDE4D
11
Show member pathways
11.64 ADRB1 ADRB2 HTR2B
12 11.52 ADRB1 HTR2B
13
Show member pathways
11.5 PDE4B PDE4C PDE4D
14 11.38 ADRB1 ADRB2
15 11.3 ADRB1 ADRB2
16 11.27 ADRB1 ADRB2
17 11.19 ADRB1 ADRB2 PDE4B PDE4C PDE4D
18 10.84 ADRB1 ADRB2

GO Terms for Ocular Hypotension

Cellular components related to Ocular Hypotension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated calcium channel complex GO:0005891 8.62 PDE4B PDE4D

Biological processes related to Ocular Hypotension according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.85 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
2 cellular response to lipopolysaccharide GO:0071222 9.6 PDE4B PDE4D
3 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.59 ADRB1 ADRB2
4 neutrophil chemotaxis GO:0030593 9.58 PDE4B PDE4D
5 positive regulation of interferon-gamma production GO:0032729 9.58 PDE4B PDE4D
6 response to cold GO:0009409 9.57 ADRB1 ADRB2
7 activation of adenylate cyclase activity GO:0007190 9.56 ADRB1 ADRB2
8 brown fat cell differentiation GO:0050873 9.55 ADRB1 ADRB2
9 smooth muscle contraction GO:0006939 9.54 HTR2B PDE4D
10 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.52 ADRB1 ADRB2
11 positive regulation of interleukin-2 production GO:0032743 9.51 PDE4B PDE4D
12 cellular response to epinephrine stimulus GO:0071872 9.49 PDE4B PDE4D
13 negative regulation of multicellular organism growth GO:0040015 9.48 ADRB1 ADRB2
14 regulation of cardiac muscle cell contraction GO:0086004 9.46 PDE4B PDE4D
15 adrenergic receptor signaling pathway GO:0071875 9.43 ADRB2 PDE4D
16 G-protein coupled receptor signaling pathway GO:0007186 9.43 ADRB1 ADRB2 HTR2B PDE4B PDE4C PDE4D
17 diet induced thermogenesis GO:0002024 9.4 ADRB1 ADRB2
18 heat generation GO:0031649 9.32 ADRB1 ADRB2
19 norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure GO:0002025 9.26 ADRB1 ADRB2
20 negative regulation of relaxation of cardiac muscle GO:1901898 9.16 PDE4B PDE4D
21 cAMP catabolic process GO:0006198 8.8 PDE4B PDE4C PDE4D

Molecular functions related to Ocular Hypotension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.61 ADRB1 ADRB2 HTR2B
2 ion channel binding GO:0044325 9.48 PDE4B PDE4D
3 drug binding GO:0008144 9.46 HTR2B PDE4D
4 cAMP binding GO:0030552 9.4 PDE4B PDE4D
5 3,5-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.37 PDE4B PDE4D
6 adrenergic receptor activity GO:0004935 9.32 ADRB1 ADRB2
7 epinephrine binding GO:0051379 9.26 ADRB1 ADRB2
8 norepinephrine binding GO:0051380 9.16 ADRB1 ADRB2
9 phosphoric diester hydrolase activity GO:0008081 9.13 PDE4B PDE4C PDE4D
10 3,5-cyclic-AMP phosphodiesterase activity GO:0004115 8.8 PDE4B PDE4C PDE4D

Sources for Ocular Hypotension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....